drugset / Trial / NCT03536949
Study of Safety of RVL-1201 in Treatment of Blepharoptosis
RandomizedParallel-groupTriple-blindTreatment
Summary
Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
Timeline
- Start
- 2018-06-20
- Primary completion
- 2019-03-14
- Completion
- 2019-03-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxymetazoline | Other / unclassified | 0.1 % | Other |